drugset
drugset / Trial / NCT01209793

Safety and Tolerability Study of REGN846 (SAR302352) in Healthy Volunteers

NCT01209793 ↗

Phase 1 Completed 40 enrolled Regeneron Pharmaceuticals Sanofi · collab
RandomizedSingle-groupDouble-blindTreatment

Summary

This study is being conducted to assess the safety and tolerability of a single ascending intravenous (IV) dose of REGN846 in healthy volunteers.

Timeline

Start
2010-11
Primary completion
2011-09
Completion
2011-09

Drugs

EvaluationDrugModalityDoseRoute
Subject REGN846 Unknown — Intravenous

Indications

No indication recorded.